ADC Therapeutics S.A. (ADCT) Stock Overview
Explore ADC Therapeutics S.A.’s financial performance, market position, analyst ratings, and future outlook.
ADC Therapeutics S.A. (ADCT)
Key Financials
Key Financials
Market Cap
139.9M
P/E Ratio
-1.06
EPS (TTM)
$-1.05
ROE
0.65%
ADCT Stock Analysis & Investment Overview (NYSE)
Our AI-powered analysis of ADC Therapeutics S.A. (NYSE: ADCT) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, ADC Therapeutics S.A.'s NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ADCT on the NYSE shows an RSI of 36.62, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.43 for the NYSE listing.
Key metrics behind ADC Therapeutics S.A.'s NYSE-traded stock include a P/E ratio of -1.06 and a market capitalization of 139.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADCT on the NYSE.